PL408608A1 - Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania - Google Patents
Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzaniaInfo
- Publication number
- PL408608A1 PL408608A1 PL408608A PL40860814A PL408608A1 PL 408608 A1 PL408608 A1 PL 408608A1 PL 408608 A PL408608 A PL 408608A PL 40860814 A PL40860814 A PL 40860814A PL 408608 A1 PL408608 A1 PL 408608A1
- Authority
- PL
- Poland
- Prior art keywords
- cytisine
- pharmaceutical composition
- producing
- stable permanent
- permanent pharmaceutical
- Prior art date
Links
- ANJTVLIZGCUXLD-BDAKNGLRSA-N (-)-Cytisine Natural products C1NC[C@@H]2CN3C(=O)C=CC=C3[C@H]1C2 ANJTVLIZGCUXLD-BDAKNGLRSA-N 0.000 title abstract 3
- ANJTVLIZGCUXLD-DTWKUNHWSA-N cytisine Chemical group C1NC[C@H]2CN3C(=O)C=CC=C3[C@@H]1C2 ANJTVLIZGCUXLD-DTWKUNHWSA-N 0.000 title abstract 3
- 229940027564 cytisine Drugs 0.000 title abstract 3
- 229930017327 cytisine Natural products 0.000 title abstract 3
- ANJTVLIZGCUXLD-UHFFFAOYSA-N ent-cytisine Natural products C1NCC2CN3C(=O)C=CC=C3C1C2 ANJTVLIZGCUXLD-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 abstract 1
- 239000008119 colloidal silica Substances 0.000 abstract 1
- 235000019700 dicalcium phosphate Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Wynalazek dotyczy trwałej stałej kompozycji farmaceutycznej zawierającej jako substancję czynną cytyzynę. Kompozycja charakteryzuje się tym, że zawiera od 20% do 75% celulozy mikrokrystalicznej, substancję poślizgową i co najmniej jedną farmaceutycznie dopuszczalną substancję pomocniczą wybraną z grupy obejmującej: mannitol, krzemionkę koloidalną, wodorofosforan wapnia, przy czym co najmniej 60% cząstek cytyzyny ma wielkość od 10 µm do 200 µm.
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL408608A PL408608A1 (pl) | 2014-06-18 | 2014-06-18 | Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania |
| LTEP15001790.3T LT2957280T (lt) | 2014-06-18 | 2015-06-17 | Kieta farmacinė citizino kompozicija ir jos gamybos būdas |
| RS20190766A RS58983B1 (sr) | 2014-06-18 | 2015-06-17 | Čvrsta farmaceutska kompozicija citizina i postupak za njeno dobijanje |
| SI201530809T SI2957280T1 (sl) | 2014-06-18 | 2015-06-17 | Trden farmacevtski sestavek citizina in postopek za njegovo pripravo |
| EP15001790.3A EP2957280B1 (en) | 2014-06-18 | 2015-06-17 | Solid pharmaceutical composition of cytisine and process for preparation thereof |
| PL15001790T PL2957280T3 (pl) | 2014-06-18 | 2015-06-17 | Stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania |
| PT15001790T PT2957280T (pt) | 2014-06-18 | 2015-06-17 | Composição farmacêutica sólida de citisina e processo para a sua preparação |
| TR2019/09836T TR201909836T4 (tr) | 2014-06-18 | 2015-06-17 | Sitisinin katı farmasötik bileşimi ve bunun hazırlanması için proses. |
| HUE15001790 HUE044804T2 (hu) | 2014-06-18 | 2015-06-17 | Citizint tartalmazó szilárd gyógyszerkészítmény és eljárás elõállítására |
| ES15001790T ES2732711T3 (es) | 2014-06-18 | 2015-06-17 | Composición farmacéutica estable sólida de citisina y proceso para la preparación de la misma |
| DK15001790.3T DK2957280T3 (da) | 2014-06-18 | 2015-06-17 | Farmaceutisk faststofsammensætning af cytisin og fremgangsmåde til fremstilling deraf |
| HRP20191217TT HRP20191217T1 (hr) | 2014-06-18 | 2019-07-04 | Čvrsti farmaceutski sastav citizina i postupak pripreme istog |
| CY20191100733T CY1121986T1 (el) | 2014-06-18 | 2019-07-10 | Στερεη φαρμακευτικη συνθεση κυtισινης και διαδικασια για την παρασκευη της |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL408608A PL408608A1 (pl) | 2014-06-18 | 2014-06-18 | Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL408608A1 true PL408608A1 (pl) | 2015-12-21 |
Family
ID=54011933
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL408608A PL408608A1 (pl) | 2014-06-18 | 2014-06-18 | Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania |
| PL15001790T PL2957280T3 (pl) | 2014-06-18 | 2015-06-17 | Stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15001790T PL2957280T3 (pl) | 2014-06-18 | 2015-06-17 | Stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2957280B1 (pl) |
| CY (1) | CY1121986T1 (pl) |
| DK (1) | DK2957280T3 (pl) |
| ES (1) | ES2732711T3 (pl) |
| HR (1) | HRP20191217T1 (pl) |
| HU (1) | HUE044804T2 (pl) |
| LT (1) | LT2957280T (pl) |
| PL (2) | PL408608A1 (pl) |
| PT (1) | PT2957280T (pl) |
| RS (1) | RS58983B1 (pl) |
| SI (1) | SI2957280T1 (pl) |
| TR (1) | TR201909836T4 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201602145D0 (en) | 2016-02-05 | 2016-03-23 | Achieve Pharma Uk Ltd | Salt |
| EP3598968A1 (en) | 2018-07-23 | 2020-01-29 | Adamed Pharma S.A. | Solid pharmaceutical cytisine composition |
| BG67408B1 (bg) * | 2019-04-12 | 2022-01-17 | Софарма Ад | Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости |
| CN115487158A (zh) * | 2021-06-18 | 2022-12-20 | 北京万全德众医药生物技术有限公司 | 一种金雀花碱片剂及其制备方法 |
| US20250186417A1 (en) * | 2023-12-12 | 2025-06-12 | Achieve Life Sciences, Inc. | Cytisine formulations |
| WO2025128716A1 (en) * | 2023-12-12 | 2025-06-19 | Achieve Life Sciences, Inc. | Smoking cessation compounds having reduced nitrosamines and associated methods |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59500217A (ja) | 1982-02-22 | 1984-02-16 | ベロルススキ− ナウチノ− イスレドワ−チエルスキ− サニタルノ− ギギエニチエスキ− インスチツ−ト | 抗ニコチン効果を有する製剤およびその製造法 |
| EP0857172B1 (en) | 1996-05-20 | 1999-08-04 | Andrej Zinovyevich Vitik | Phosphorus containing cythesine derivatives |
| BG65536B1 (bg) | 2004-04-16 | 2008-11-28 | "Софарма" Ад | Лекарствена форма, съдържаща цитизин |
| EP2233134A1 (en) * | 2009-03-27 | 2010-09-29 | McNeil AB | Multi-portion intra-oral dosage form with organoleptic properties |
| PL220354B1 (pl) | 2012-11-19 | 2015-10-30 | Aflofarm Fabryka Leków Spółka Z Ograniczoną Odpowiedzialnością | Stała postać dawkowania zawierająca zmikronizowaną cytyzynę oraz sposób jej otrzymywania |
-
2014
- 2014-06-18 PL PL408608A patent/PL408608A1/pl unknown
-
2015
- 2015-06-17 TR TR2019/09836T patent/TR201909836T4/tr unknown
- 2015-06-17 LT LTEP15001790.3T patent/LT2957280T/lt unknown
- 2015-06-17 PL PL15001790T patent/PL2957280T3/pl unknown
- 2015-06-17 SI SI201530809T patent/SI2957280T1/sl unknown
- 2015-06-17 HU HUE15001790 patent/HUE044804T2/hu unknown
- 2015-06-17 ES ES15001790T patent/ES2732711T3/es active Active
- 2015-06-17 PT PT15001790T patent/PT2957280T/pt unknown
- 2015-06-17 RS RS20190766A patent/RS58983B1/sr unknown
- 2015-06-17 EP EP15001790.3A patent/EP2957280B1/en not_active Revoked
- 2015-06-17 DK DK15001790.3T patent/DK2957280T3/da active
-
2019
- 2019-07-04 HR HRP20191217TT patent/HRP20191217T1/hr unknown
- 2019-07-10 CY CY20191100733T patent/CY1121986T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20191217T1 (hr) | 2019-10-18 |
| ES2732711T3 (es) | 2019-11-25 |
| TR201909836T4 (tr) | 2019-07-22 |
| RS58983B1 (sr) | 2019-08-30 |
| PL2957280T3 (pl) | 2019-09-30 |
| DK2957280T3 (da) | 2019-07-22 |
| SI2957280T1 (sl) | 2019-08-30 |
| EP2957280A1 (en) | 2015-12-23 |
| CY1121986T1 (el) | 2020-10-14 |
| PT2957280T (pt) | 2019-07-23 |
| EP2957280B1 (en) | 2019-04-17 |
| LT2957280T (lt) | 2019-07-25 |
| HUE044804T2 (hu) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR129504A2 (es) | Hidrato de diclorhidrato de omecamtiv mecarbil, formas cristalinas, y composiciones farmacéuticas | |
| EP3398948A3 (en) | 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof | |
| SG10201804817TA (en) | Delayed release compositions of linaclotide | |
| MX2016010056A (es) | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. | |
| UA109868C2 (ru) | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) | |
| MX348823B (es) | Formulaciones estables de linaclotida. | |
| MX2016016593A (es) | Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos. | |
| PL408608A1 (pl) | Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania | |
| GT201600137A (es) | Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina | |
| EP4592275A3 (en) | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| MD4563B1 (ro) | Produs de comicronizare cu conţinut de acetat de ulipristal | |
| MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
| MX2015000179A (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
| PH12017502149A1 (en) | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester | |
| NZ712341A (en) | A crystalline form of an anxiolytic compound | |
| IN2013MU01177A (pl) | ||
| CA3003108A1 (en) | Storage stable composition comprising rifaximin alpha | |
| MX2016013561A (es) | Activadores de herg policiclicos. | |
| MA39877A (fr) | Formes solides d'un composé pharmaceutiquement actif | |
| MX385513B (es) | Composiciones farmaceuticas que comprenden safinamida. | |
| WO2016197042A8 (en) | Modified or targeted release formulations of linaclotide | |
| WO2016069542A3 (en) | Lactone compounds and methods of making and using same | |
| GEP201706614B (en) | Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process | |
| MX2012002209A (es) | Formulaciones de liberacion controlada de compuestos de anabaseina y usos de los mismos. |